Jefferies Group restated their buy rating on shares of Zoetis (NYSE:ZTS) in a report issued on Friday. The firm currently has a $96.00 price target on the stock. Jefferies Group also issued estimates for Zoetis’ Q1 2018 earnings at $0.71 EPS, FY2018 earnings at $3.07 EPS, FY2019 earnings at $3.56 EPS, FY2020 earnings at $4.11 EPS, FY2021 earnings at $4.56 EPS and FY2022 earnings at $5.09 EPS.
A number of other research analysts also recently commented on ZTS. Credit Suisse Group increased their price objective on Zoetis from $83.00 to $89.00 and gave the company an outperform rating in a report on Thursday, April 5th. ValuEngine upgraded Zoetis from a hold rating to a buy rating in a report on Monday, April 2nd. BMO Capital Markets reiterated a hold rating on shares of Zoetis in a report on Monday, January 8th. Piper Jaffray reiterated a buy rating and issued a $86.00 price objective on shares of Zoetis in a report on Thursday, January 18th. Finally, Citigroup upgraded Zoetis from a neutral rating to a buy rating and set a $85.00 price objective on the stock in a report on Thursday, January 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the stock. Zoetis has an average rating of Buy and an average price target of $80.89.
Shares of NYSE ZTS opened at $83.57 on Friday. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77. Zoetis has a 1-year low of $53.00 and a 1-year high of $85.73. The stock has a market cap of $40,741.90, a price-to-earnings ratio of 34.82, a P/E/G ratio of 1.88 and a beta of 0.96.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be paid a dividend of $0.126 per share. The ex-dividend date is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.60%. Zoetis’s dividend payout ratio is presently 20.83%.
In related news, insider Heidi C. Chen sold 7,383 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $84.71, for a total transaction of $625,413.93. Following the transaction, the insider now owns 20,162 shares in the company, valued at approximately $1,707,923.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Roman Trawicki sold 8,568 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $83.10, for a total value of $712,000.80. Following the transaction, the insider now owns 11,457 shares in the company, valued at approximately $952,076.70. The disclosure for this sale can be found here. Insiders have sold a total of 112,952 shares of company stock worth $9,219,843 in the last 90 days. 0.35% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Polen Capital Management LLC acquired a new stake in Zoetis during the 4th quarter worth approximately $285,967,000. Bessemer Group Inc. lifted its position in Zoetis by 231,590.8% during the 4th quarter. Bessemer Group Inc. now owns 2,117,654 shares of the company’s stock worth $152,557,000 after acquiring an additional 2,116,740 shares during the period. BlackRock Inc. lifted its position in Zoetis by 3.8% during the 4th quarter. BlackRock Inc. now owns 38,485,542 shares of the company’s stock worth $2,772,498,000 after acquiring an additional 1,394,156 shares during the period. Millennium Management LLC lifted its position in Zoetis by 208.1% during the 4th quarter. Millennium Management LLC now owns 1,984,470 shares of the company’s stock worth $142,961,000 after acquiring an additional 1,340,378 shares during the period. Finally, Acadian Asset Management LLC lifted its position in Zoetis by 111.3% during the 4th quarter. Acadian Asset Management LLC now owns 1,709,352 shares of the company’s stock worth $123,143,000 after acquiring an additional 900,261 shares during the period. Hedge funds and other institutional investors own 92.44% of the company’s stock.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.